Latest Headlines

  1. Sarcomatrix Therapeutics Announces Strategic Collaboration With RNA Advisors To Advance Drug Development Strategy 3/11/2025

    Sarcomatrix Therapeutics, a biopharmaceutical company pioneering novel treatments for muscular dystrophies and age-related muscle degeneration, today announced a strategic collaboration withRNA Advisors, a leading life sciences advisory firm specializing in valuation, strategy, and transaction support.

  2. Sydnexis Announces FDA Acceptance Of New Drug Application For SYD-101 For The Treatment Of Progression Of Pediatric Myopia 3/11/2025

    Sydnexis, Inc. (www.sydnexis.com), a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for SYD-101 and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025.

  3. Nosis Biosciences Announces Research Collaboration And Option Agreement With Daiichi Sankyo To Develop Cell-Targeted RNA Medicines 3/11/2025

    Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today announced it entered into a Research Collaboration and Option Agreement with Daiichi Sankyo.

  4. Boehringer Ingelheim Partners With Veeva To Launch 'One Medicine Platform' 3/11/2025

    Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud.

  5. Lundbeck's Potential Treatment For Multiple System Atrophy Granted Orphan Drug Designation In Japan 3/10/2025

    The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

  6. Scientists Unveil World-Leading Technology To Speed Up Drug Discovery 3/7/2025

    Scientists from Newcastle University, with funding from Versus Arthritis, have developed a unique approach to bioprinting cell-filled gels that can closely mimic human tissues, earning it a patent in the US and Europe.

  7. Nona Biosciences Integrates Cutting-Edge AI Technology To Enhance Its Fully Human Antibody Platform, Accelerating Antibody Discovery Across Key Therapeutic Areas 3/7/2025

    Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced to unveil its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM.

  8. UTSA Chemist To Advance Drug Discovery Using Light To Activate Catalysts 3/6/2025

    A UTSA chemist is pioneering a novel approach to drug discovery by using catalysts that are triggered by light. This innovative approach, paired with advanced automated lab techniques, could lead to the next generation of antibiotics.

  9. HanAll Biopharma Announces Orphan Drug Designation For Batoclimab In Japan For Active Thyroid Eye Disease 3/6/2025

    HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, announced that Batoclimab, an anti-FcRn treatment being developed for a range of autoimmune diseases, has received Orphan Drug Designation (ODD) from the Ministry of Health, Labor and Welfare (MHLW) in Japan for active Thyroid Eye Disease (TED).

  10. Children's Hospital Of Philadelphia Researchers Use A 'Trojan Horse' Approach To Develop New Antimalarial Drugs 3/5/2025

    Antimalarial drug resistance is a pressing issue in combating the spread of malaria worldwide. In a new study, researchers from Children's Hospital of Philadelphia (CHOP) discovered a key process where malarial parasites take up a human blood cell enzyme, which could provide a new approach for antimalarial treatment.